| |
|
|
Emerging Trends in Corporate White Collar Criminal and Regulatory Law--A Twenty-Year Overview |
|
|
|
Chapter 1: |
Internal Investigation of Suspected Wrongdoing by Corporate Employees |
|
|
- § 1:1 : Introduction1-2
- § 1:2 : Steps to Take at the Outset of an Investigation1-3
- § 1:2.1 : Who Conducts the Investigation— In-House Counsel or Outside Attorneys?1-3
- § 1:2.2 : Defining the Scope of the Investigation1-4
- § 1:2.3 : Doing a Conflicts Check1-5
- § 1:2.4 : Expertise of Counsel1-6
- § 1:3 : Investigative Tools1-7
- § 1:3.1 : Document Review1-7
- § 1:3.2 : Recovering Expenses Incurred During Internal Investigations1-8
- § 1:3.3 : Employee Interviews1-9
- [A] : Presence of In-House Counsel at the Interview1-9
- [B] : Conducting the Interview1-10
- [C] : Separate Counsel for the Employee1-12
- § 1:3.4 : Whether or Not to Prepare a Written Report1-14
- § 1:3.5 : Polygraph Testing1-14
- § 1:3.6 : Workplace Searches1-16
- § 1:3.7 : Workplace Surveillance1-16
- § 1:3.8 : Drug and Alcohol Testing1-17
- § 1:4 : Special Issues in Internal Investigations1-18
- § 1:4.1 : The Current Financial Market Meltdown and Global Economic Crisis1-18
- [A] : The Origins of a Financial Market Meltdown and Global Economic Crisis1-18
- [B] : The Law Enforcement Response1-25
- [B][1] : The SEC1-26
- [B][2] : The Department of Justice1-30
- [B][3] : The New York State Attorney General1-35
- [C] : Special Considerations in Internal Investigations of Subprime Debt Portfolios and Credit Default Swaps1-37
- § 1:4.2 : Obstruction of Justice1-38
- [A] : Obstruction of Justice Statutes1-38
- [B] : Document Retention Policies1-42
- [C] : Liability of Attorneys1-43
- [D] : Guidelines for Counsel1-44
- § 1:4.3 : Indemnification and Advancement of Legal Fees1-44
- [A] : Mandatory Indemnification1-45
- [B] : Permissive Indemnification1-47
- [C] : Advancement of Legal Fees and Expenses1-47
- [D] : Constitutional Issues1-48
- § 1:4.4 : Protection for Whistleblowers Against Retaliation1-50
- [A] : Under Sarbanes-Oxley1-50
- [A][1] : Civil Penalties1-50
- [A][2] : Criminal Penalties1-51
- [A][3] : Dodd-Frank Amendments Expanding Sarbanes-Oxley Whistleblower Protections1-52
- [A][4] : Retaliation Policies1-52
- [A][5] : Disciplining Whistleblowers1-53
- [B] : Under Dodd-Frank1-53
- [C] : Potential Impact on Internal Investigations and Other Considerations1-57
- § 1:5 : Practitioner’s Checklist for Conducting Internal Investigations1-58
|
|
Chapter 2: |
The Attorney-Client Privllege, Work-Product Protection, and Self-Critical Privilege In Internal Investigations |
|
|
- § 2:1 : Introduction2-2
- § 2:2 : The Attorney-Client Privilege2-2
- § 2:2.1 : Elements of the Corporate Attorney-Client Privilege2-3
- § 2:2.2 : Applicability to Experts, Attorney Agents, and the Corporation’s Former Employees2-4
- § 2:2.3 : Attorney’s Duty to Assert Privilege2-4
- § 2:2.4 : What the Privilege Does Not Cover2-4
- § 2:2.5 : The Crime-Fraud Exception2-6
- § 2:2.6 : Authority to Waive the Corporate Attorney-Client Privilege2-7
- § 2:2.7 : Effect of Inadvertent Disclosure of Privileged Information on Waiver2-7
- § 2:3 : Work-Product Protection2-10
- § 2:3.1 : Work-Product Protection Qualified2-10
- § 2:3.2 : Applicability to Materials from an Internal Investigation2-11
- § 2:3.3 : Materials Protected by the Work-Product Doctrine2-11
- § 2:4 : The Department of Justice’s Waiver Policy and the Sentencing Guidelines2-12
- § 2:4.1 : The Holder Memorandum2-12
- § 2:4.2 : The Thompson Memorandum2-14
- § 2:4.3 : The 2004 Amendments to the Federal Sentencing Guidelines2-15
- § 2:4.4 : The McCallum Memorandum2-16
- § 2:4.5 : The McNulty Memorandum2-16
- § 2:4.6 : The Principles of Federal Prosecution of Business Organizations2-17
- § 2:5 : Disclosure to the Government and Its Impact on Waiver of the Attorney-Client Privilege and Work-Product Protection2-21
- § 2:5.1 : Attorney-Client Privilege and Selective Waiver2-21
- § 2:5.2 : Work-Product Protection and Selective Waiver2-22
- § 2:6 : The Common Interest Privilege2-27
- § 2:6.1 : Applicability of the Common Interest Privilege2-27
- § 2:7 : Self-Critical Privilege2-29
- § 2:7.1 : Recognition of the Self-Critical Privilege2-29
- § 2:7.2 : Rejection of the Self-Critical Privilege2-30
- § 2:8 : Additional Practical Waiver Problems in Internal Investigations2-31
- § 2:8.1 : Internal Investigations Because of Business Necessities2-31
- § 2:8.2 : Investigation by and for Management2-32
- § 2:8.3 : Use of Regularly Employed Auditor2-33
- § 2:8.4 : The Pseudo-Hypothetical2-34
- § 2:8.5 : Disclosures to Public Relations Consultants2-34
- § 2:9 : Practitioner’s Checklist for Obtaining Benefits of Cooperation Without Waiver2-35
|
|
Chapter 3: |
Grand Jury Investigations and Multiple Representations of Witnesses |
|
|
- § 3:1 : Overview of the Grand Jury Process3-1
- § 3:1.1 : Responding to a Grand Jury Subpoena3-3
- § 3:1.2 : Computer Records and Electronic Documents3-4
- § 3:1.3 : Motions to Dismiss Grand Jury Indictments3-5
- § 3:2 : Ethical Issues in Multiple Representations Before a Grand Jury3-7
- § 3:2.1 : Ethical Considerations and Conflicts of Interest3-7
- § 3:2.2 : New York’s New Attorney Ethics Rules3-13
- § 3:2.3 : The Prosecutor’s Response3-15
- § 3:2.4 : A Carefully Thought-Out Decision3-17
- § 3:2.5 : The Judicial Response3-17
- § 3:3 : Practical Considerations When Considering Multiple Representation3-18
|
|
Chapter 4: |
Representing the Target in an SEC Investigation and in Parallel Proceedings |
|
|
- § 4:1 : SEC Investigations4-1
- § 4:1.1 : The Formal Investigation4-3
- § 4:1.2 : Cooperation Considerations4-4
- § 4:1.3 : The Impact of Whistleblower Information4-7
- § 4:1.4 : Asserting Privilege in an SEC Investigation4-11
- § 4:1.5 : Asserting the Fifth Amendment Privilege4-12
- § 4:1.6 : Multiple Representation Issues in SEC Proceedings4-14
- § 4:1.7 : Ground Rules for Testifying Before the Staff4-14
- § 4:1.8 : Rules of Evidence4-16
- § 4:1.9 : Wells Submission4-17
- § 4:1.10 : The Seaboard Factors4-18
- § 4:1.11 : SEC Guidelines for Financial Penalties4-21
- § 4:1.12 : SEC Settlements Under Scrutiny4-24
- § 4:2 : Parallel Proceedings4-26
- § 4:2.1 : Admissibility of Statements Made During Parallel Civil Proceedings4-28
- § 4:2.2 : Wiretapping and Parallel Proceedings4-31
|
|
Chapter 5: |
Responding to Searches and Seizures |
|
|
- § 5:1 : Specifics of the Warrant5-1
- § 5:2 : Execution of the Warrant5-2
- § 5:3 : Searching and Seizing Electronic Data5-3
- § 5:3.1 : Warrantless Computer Searches5-4
- § 5:3.2 : Computer Searches with a Warrant5-5
- § 5:4 : Searching and Seizing Other Electronic Communications5-8
- § 5:5 : Protecting Privileged Documents During a Search5-9
- § 5:6 : Practitioner’s Checklist for Responding to Searches and Seizures5-10
|
|
Chapter 6: |
Asset Forfeiture and Debarment |
|
|
- § 6:1 : Asset Forfeiture6-2
- § 6:1.1 : The Civil Asset Forfeiture Reform Act6-3
- § 6:1.2 : Initiation of Civil Judicial Forfeiture6-4
- [A] : Pre-Seizure “Freezing” of Assets6-4
- [B] : Pre-Forfeiture Seizure of the Assets6-4
- [C] : Pre-Trial Procedures Under Supplemental Rule G6-5
- § 6:1.3 : Civil Trial Procedure6-8
- [A] : Initial Burden on the Government6-8
- [B] : Innocent Owner Defense6-8
- [C] : Bona Fide Purchaser or Seller for Value6-9
- [D] : Knowledge or Reason to Believe Property Subject to Forfeiture6-9
- [E] : The Department of Justice Policy on Forfeiture of Attorney Fees6-12
- § 6:1.4 : Civil Judicial Forfeiture of Transferred Traceable Assets6-14
- § 6:1.5 : Seizure of Fungible Assets6-15
- § 6:1.6 : Awards of Attorney Fees to Prevailing Claimants6-16
- § 6:2 : Debarment6-18
- § 6:2.1 : Overview of Suspension and Debarment6-18
- § 6:2.2 : Consequences of Suspension and Debarment6-20
- § 6:2.3 : Term of Suspension or Debarment6-22
- § 6:2.4 : Grounds for Imposing Debarment or Suspension6-23
- § 6:2.5 : Factors Informing Agency Discretion to Debar or Suspend6-25
- § 6:2.6 : Debarment or Suspension Based on Imputation or Affiliation6-27
- [A] : Imputation6-27
- [B] : Affiliation6-28
- § 6:3 : Practical Considerations in Addressing Debarment and Suspension6-30
|
|
Chapter 7: |
Corporate Compliance Programs Under the Organizational Sentencing Guidelines |
|
|
- § 7:1 : Introduction7-2
- § 7:2 : The Organizational Sentencing Guidelines Methodology7-5
- § 7:2.1 : Base Fine7-5
- § 7:2.2 : Culpability Score—Minimum/Maximum Multipliers7-6
- § 7:2.3 : Applicable Fine Range7-8
- § 7:2.4 : Determining the Actual Fine7-8
- § 7:2.5 : Disgorgement7-9
- § 7:2.6 : Fines for Antitrust Offenses7-9
- § 7:3 : Remedial Sanctions and Probation Under the Guidelines7-9
- § 7:4 : Criteria for an Effective Program to Prevent and Detect Violation of Law7-11
- § 7:5 : Section 8B2.1(b)(1)7-12
- § 7:6 : Section 8B2.1(b)(2)7-14
- § 7:7 : Section 8B2.1(b)(3)7-17
- § 7:8 : Section 8B2.1(b)(4)7-18
- § 7:9 : Section 8B2.1(b)(5)7-19
- § 7:9.1 : Internal Auditing7-20
- § 7:9.2 : Employee Hotlines and the Ombudsman7-21
- § 7:9.3 : Business Ethics Questionnaires7-22
- § 7:9.4 : Gap Analysis7-24
- § 7:10 : Section 8B2.1(b)(6)7-25
- § 7:10.1 : Termination Under New York Law of Employees Implicated in or Under Suspicion of a Violation of Law7-26
- § 7:10.2 : Termination Under California Law of Employees Implicated in or Under Suspicion of a Violation of Law7-28
- § 7:10.3 : Termination Under New York Law of an Employee Formally Accused (i.e., Arrested or Indicted) of a Violation of Law7-30
- § 7:10.4 : Termination Under California Law of an Employee Formally Accused (i.e., Arrested or Indicted) of a Violation of Law7-30
- § 7:10.5 : Executive Contract Issues7-31
- § 7:10.6 : Union Contract Issues7-31
- § 7:10.7 : Practical Considerations7-32
- § 7:10.8 : General Principles Governing Termination of an Employee Convicted of a Crime (Misdemeanor or Felony)7-32
- § 7:11 : Section 8B2.1(b)(7)7-33
- § 7:12 : Section 8B2.1(c) (Risk Assessment)7-33
- § 7:13 : Waiver of Privilege7-34
- § 7:14 : Caremark Liability7-35
|
|
Chapter 8: |
Leniency Programs and Policies |
|
|
- § 8:1 : Introduction8-2
- § 8:2 : Comparison Between the McNulty Memorandum and the Revised Principles8-2
- § 8:2.1 : The McNulty Memorandum8-2
- § 8:2.2 : Deputy Attorney General Filip’s Revised “Principles of Federal Prosecution of Business Organizations”8-7
- § 8:3 : Department of Justice Guidelines for Prosecuting Organizational Environmental Offenders8-10
- § 8:3.1 : Introduction8-10
- [A] : Factors for Leniency8-11
- § 8:3.2 : EPA Audit Standards and Leniency Policies8-13
- § 8:3.3 : Compliance and Remediation Programs8-15
- § 8:3.4 : DOJ Guidelines Hypothetical Scenarios8-15
- [A] : The “Good” Company8-15
- [B] : The “Bad” Company8-16
- [C] : Companies Between the Extremes8-16
- § 8:4 : Department of Defense Voluntary Disclosure Program8-17
- § 8:4.1 : Recognition As a Volunteer8-18
- § 8:4.2 : The Voluntary Disclosure Process8-18
- [A] : Preliminary Acceptance8-19
- [B] : Agreement to Cooperate with the Investigation—The XYZ Agreement8-19
- [C] : Contractor’s Disclosure8-19
- [D] : The Government’s Investigation8-20
- [E] : Collateral Use of Disclosed Material8-21
- [F] : Payments by Contractors8-21
- § 8:4.3 : Contractor Code of Business Ethics and Conduct8-21
- § 8:4.4 : Display of Hotline Poster(s)8-22
- § 8:5 : Antitrust Division Corporate Leniency Policy8-23
- § 8:5.1 : Pre-Investigation Amnesty8-24
- § 8:5.2 : Alternative Grounds for Amnesty8-24
- § 8:5.3 : Leniency for Corporate Directors, Officers, and Employees8-25
- § 8:5.4 : Potential Benefits of “Second-In” Cooperation8-26
- § 8:6 : SEC Leniency Policies8-27
- § 8:6.1 : The Seaboard Guidelines8-27
- § 8:6.2 : Leniency for Individuals8-29
|
|
Chapter 9: |
Deferred Prosecution Agreements |
|
|
- § 9:1 : Introduction9-1
- § 9:1.1 : What Is a DPA?9-3
- § 9:1.2 : Why Has Deferred Prosecution of Corporations Become So Common?9-6
- § 9:1.3 : DPA or Declination?9-8
- § 9:1.4 : The Terms of the Agreement9-10
- § 9:1.5 : DOJ Guidance on the Use of Corporate Monitors9-11
- § 9:2 : Practical Considerations in Negotiating Deferred Prosecution Agreements9-12
|
|
Chapter 10: |
Representing the Drug or Medical Device Manufacturer in a Criminal Investigation |
|
|
- § 10:1 : Introduction10-1
- § 10:2 : The Statutory and Regulatory Scheme10-2
- § 10:2.1 : The FDCA10-2
- § 10:2.2 : The Anti-Kickback Statute10-5
- § 10:2.3 : The False Claims Act10-5
- § 10:2.4 : Other Regulatory Tools10-5
- § 10:3 : Recent Developments in Enforcement Actions10-8
- § 10:3.1 : Enforcement Actions Against Pharmaceutical Manufacturers10-8
- § 10:3.2 : Enforcement Actions Against Medical Device Manufacturers10-13
- § 10:3.3 : Sorrell and First Amendment Challenges10-16
- § 10:4 : Recent FDA Warning Letters10-16
- § 10:4.1 : To Pharmaceutical Companies Regarding Promotional Materials10-16
- § 10:4.2 : To Medical Device Manufacturers Concerning Good Manufacturing Practices10-20
- § 10:5 : Compliance Strategies10-21
- § 10:6 : Responding to a Criminal Investigation10-23
|
|
Chapter 11: |
Prosecutions for Violations of U.S. Export Controls |
|
|
- § 11:1 : Introduction11-2
- § 11:2 : The Export Control Regulatory Framework11-3
- § 11:2.1 : International Traffic in Arms Regulations11-3
- § 11:2.2 : Export Administration Regulations11-5
- § 11:2.3 : Determining Appropriate Jurisdiction11-6
- § 11:3 : Enforcement11-7
- § 11:3.1 : Penalties for ITAR Violations11-10
- § 11:3.2 : Penalties for EAR Violations11-11
- § 11:4 : Compliance with Export Control Regulations11-11
- § 11:4.1 : Corporate Compliance Programs11-11
- § 11:4.2 : Agency Guidance11-12
- § 11:4.3 : “Know Your Customer”11-13
- § 11:5 : Responding to Violations11-15
- § 11:5.1 : Voluntary Disclosure Prior to Commencement of a Government Inves-tigation11-15
- [A] : Notification and Documentation Requirements11-16
- [B] : Penalty Enforcement and Mitigation11-17
- [C] : The Decision to Disclose Voluntarily11-17
- § 11:5.2 : Defending Export Control Violations in a Government Investigation11-19
|
|
Chapter 12: |
Money Laundering |
|
|
- § 12:1 : Introduction12-1
- § 12:1.1 : The Money Laundering Statutes12-2
- § 12:1.2 : Suspicious Activity Reports12-7
- § 12:1.3 : Currency Transaction Reports12-9
- [A] : Requirements12-9
- [B] : Structuring to Avoid CTRs12-10
- § 12:2 : Money Laundering by Corrupt Foreign Leaders12-11
- § 12:2.1 : Interagency Money Laundering Guidance12-11
- [A] : Account Opening12-14
- [B] : Account Transaction Scrutiny12-15
- [C] : Suspicious Activity Reporting12-16
- § 12:2.2 : Special Issues Relating to Iran12-16
- § 12:3 : Foreign Correspondent Banking12-19
- § 12:3.1 : 2012 HSBC Case Study12-20
- § 12:3.2 : Payable-Through Accounts12-23
- § 12:4 : Money Laundering by Drug Cartels12-24
|
|
Chapter 13: |
Advising Witnesses in Light of Perjury Statutes |
|
|
- § 13:1 : Introduction13-1
- § 13:1.1 : Federal Perjury Statutes13-2
- § 13:1.2 : False Statements Statute13-3
- § 13:2 : Materiality13-4
- § 13:2.1 : Standard for Materiality13-4
- § 13:2.2 : Literal Truth Defense13-5
- § 13:3 : Perjury Prosecution Absent Prosecution for the Underlying Offense13-7
- § 13:4 : Dangers of Crossing the Line13-11
- § 13:5 : Perjury Traps13-12
- § 13:6 : Conclusion13-14
|
|
Chapter 14: |
The Foreign Corrupt Practices Act and the International Conventions on Bribery |
|
|
- § 14:1 : Introduction14-1
- § 14:2 : The Foreign Corrupt Practices Act14-8
- § 14:2.1 : Who Is Subject to the FCPA?14-9
- § 14:2.2 : What Is Prohibited by the FCPA?14-11
- § 14:2.3 : Exceptions and Defenses14-16
- § 14:2.4 : Books-and-Records Violations14-19
- § 14:2.5 : The Future of the FCPA14-24
- § 14:3 : U.K. Bribery Act 201014-26
- § 14:3.1 : The General Elements of a Bribery Act Violation14-27
- § 14:3.2 : “Failure to Prevent Bribery” Offense; “Adequate Procedures” Affirmative Defense14-29
- § 14:3.3 : The Bribery Act Compared to the FCPA14-30
- § 14:3.4 : Final Implementation of the Bribery Act14-33
- § 14:4 : International Conventions on Bribery14-33
- § 14:5 : Alternative Bases of Jurisdiction/“Improper Advantage”14-36
- § 14:6 : Practitioner’s FCPA14-39
|
|
Chapter 15: |
Representation of Companies in Criminal Antitrust Investigations |
|
|
- § 15:1 : Introduction15-2
- § 15:2 : Elements of a Sherman Antitrust Criminal Prosecution15-2
- § 15:2.1 : Conspiracy15-3
- § 15:2.2 : Criminal Intent15-4
- § 15:2.3 : Interstate Nexus15-5
- § 15:2.4 : Statute of Limitations15-5
- § 15:3 : The Department of Justice Policy for Prosecution of Sherman Act Cases15-6
- § 15:4 : Criminal Penalties15-7
- § 15:4.1 : Individual Sentences15-8
- [A] : Sentencing of Individuals15-8
- [B] : Extradition of Foreign Executives15-9
- § 15:4.2 : Corporate Fines15-10
- [A] : Calculation of Fines15-10
- [B] : Recently Imposed Fines15-14
- § 15:5 : DOJ Corporate Leniency Policy15-15
- § 15:5.1 : Pre-Investigation Amnesty15-17
- § 15:5.2 : Alternative Grounds for Amnesty15-18
- § 15:5.3 : Antitrust Division’s 2008 Model Conditional Leniency Letters and FAQ15-19
- § 15:5.4 : Leniency for Corporate Directors, Officers, and Employees15-20
- § 15:5.5 : Potential Benefits of “Second-In” Cooperation15-21
- § 15:6 : Foreign Application of Antitrust Laws15-22
- § 15:7 : State Antitrust Prosecutions15-26
- § 15:8 : Antitrust Compliance Strategies15-28
|
|
Chapter 16: |
Government Investigations Under the False Claims Act and Its Qui Tam Provisions |
|
|
- § 16:1 : Introduction16-2
- § 16:2 : The FCA Statute16-3
- § 16:2.1 : Liability and Damages Provisions16-3
- § 16:2.2 : Qui Tam Provisions16-5
- [A] : Complaint Filed Under Seal16-6
- [B] : Provisions Allowing Relators to Share in Monetary Recovery16-7
- [C] : Authority over Settlement16-8
- § 16:3 : Steps of a Government Investigation16-9
- § 16:3.1 : Agency Subpoenas16-9
- § 16:3.2 : Civil Investigative Demands16-10
- § 16:3.3 : The Government’s Decision to Intervene16-10
- § 16:4 : Elements of FCA Liability16-11
- § 16:4.1 : Claim16-11
- § 16:4.2 : Intent16-13
- § 16:4.3 : Materiality16-14
- § 16:4.4 : Causation16-18
- § 16:5 : What Conduct Is Covered16-19
- § 16:5.1 : Off-Label Marketing16-19
- [A] : Rule 9(b) Issues16-22
- [B] : False Statements16-24
- [C] : Causation and Damages Issues16-27
- § 16:5.2 : Anti-Kickback16-28
- § 16:5.3 : Pharmaceutical Pricing Cases16-30
- § 16:6 : Defenses16-31
- § 16:6.1 : Statute of Limitations16-31
- § 16:6.2 : Tax Exclusion16-33
- § 16:7 : Special Defenses Against a Qui Tam Relator16-34
- § 16:7.1 : Public Disclosure Bar16-34
- § 16:7.2 : Original Source16-37
- § 16:7.3 : First-to-File Bar16-39
- § 16:8 : Protection of Whistleblower16-40
- § 16:9 : Other Whistleblower Laws16-42
- § 16:9.1 : Tax Whistleblower Law16-42
- § 16:9.2 : Securities Whistleblower Law16-43
|
|
Chapter 17: |
Appendix A: Thompson Memorandum |
|
|
|
Chapter 18: |
Appendix B: Holder Memorandum |
|
|
|
Chapter 19: |
Appendix C: McCallum Memorandum |
|
|
|
Chapter 20: |
Appendix D: Public Hearing Held by the Ad Hoc Advisory Group on the Organizational Sentencing Guidelines |
|
|
|
Chapter 21: |
Appendix E: Comey Interview |
|
|
|
Chapter 22: |
Appendix F: Model Confidentiality Agreement with U.S. Securities and Exchange Commission |
|
|
|
Chapter 23: |
Appendix G: Association of the Bar of the City of New York Committee on Professional and Judicial Ethics Formal Opinion 2004-02--Representing Corporations and Their Constituents in the Context of Governmental Investigations |
|
|
|
Chapter 24: |
Appendix H: Seaboard Report |
|
|
|
Chapter 25: |
Appendix I: Sentencing Guideline Manual: Chapter 8--Sentencing of Organizations |
|
|
|
Chapter 26: |
Appendix J: NYSBA Ethics Opinion 650 |
|
|
|
Chapter 27: |
Appendix K: United States Department of Justice Factors in Decisions on Criminal Prosecutions for Environmental Violations in the Context of Significant Voluntary Compliance or Disclosure Efforts by the Violator |
|
|
|
Chapter 28: |
Appendix L: Environmental Protection Agency: Incentives for Self-Policing: Discovery, Disclosure, Correction and Prevention of Violations |
|
|
|
Chapter 29: |
Appendix M: Department of Defense Voluntary Disclosure Program |
|
|
|
Chapter 30: |
Appendix N: United States Department of Justice Antitrust Division Corporate Leniency Policy |
|
|
|
Chapter 31: |
Appendix O: United States Department of Justice Antitrust Division Leniency Policy for Individuals |
|
|
|
Chapter 32: |
Appendix P: Guidance on Enhanced Scrutiny for Transactions That May Involve the Proceeds of Foreign Official Corruption |
|
|
|
Chapter 33: |
Appendix Q: McNulty Memorandum |
|
|
|
Chapter 34: |
Appendix R: Principles of Federal Prosecution of Business Organizations |
|
|
|
Chapter 35: |
September 2008 Special Report |
|
|
|
Chapter 36: |
Index to Deskbook on Internal Investigations Corporate Compliance and White Collar Issues |
|
|